The clinical management of cryptogenic fibrosing alveolitis presents difficulties because both the prognosis and the response to treatment vary considerably in different patients.' Recent research into this condition has therefore attempted to find markers of disease activity and methods of predicting the response to treatment, so that patients who need treatment can be treated promptly and appropriately.
The clinical management of cryptogenic fibrosing alveolitis presents difficulties because both the prognosis and the response to treatment vary considerably in different patients.' Recent research into this condition has therefore attempted to find markers of disease activity and methods of predicting the response to treatment, so that patients who need treatment can be treated promptly and appropriately.
On the basis of histological studies excess collagen production has been assumed to be an essential feature of cryptogenic fibrosing alveolitis, but this has not been biochemically proved.2 Recently, interest in the role of collagen in cryptogenic fibrosing alveolitis has been revived by the finding of several Address for reprint requests: Dr JME Kirk, Biochemistry Unit, Cardiothoracic Institute, Brompton Hospital, London SW3 6HP.
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Methods
Seventy one patients with cryptogenic fibrosing alveolitis were studied, of whom 11 were excluded from subsequent analysis because of overt rheumatoid arthritis or abnormal results in liver function tests, both of which are known to be associated with raised serum procollagen peptide concentrations.'2 The remaining 60 patients were compared with 45 normal subjects. All patients fulfilled the diagnostic criteria described by Turner-Warwick and colleagues.'3 Serum procollagen peptide concentration was measured in 10 patients with nonfibrosing lung disorders. Twenty three patients with cryptogenic fibrosing alveolitis were not having treatment at the time of sampling, and the results from these patients were compared with those from a group of 21 age and sex matched control subjects. Treatment with either high dose steroids or steroids with cyclophosphamide was started subsequently in 17 of these patients; procollagen peptide concentrations were measured before treatment and again three to six months later. In 10 patients repeat procollagen peptide measurements were made on several more occasions, up to 18 months after starting treatment. Normal control samples were taken from members of staff of the Brompton Hospital, the Cardiothoracic Institute, and the Chester Beatty Research Institute. The 10 patients with nonfibrosing lung disorders were inpatients at the Brompton Hospital who had been admitted because of an acute exacerbation of chronic obstructive lung disease (5), asthma (2), or bronchiectasis (3).
The ratio of type III to total type I + III collagen was measured biochemically (as described later) in five postmortem samples and seven open lung biopsy samples, and these results were compared with the serum procollagen peptide concentration measured just before death or biopsy.
CLINICAL ANALYSIS
The clinical course of the patients' disease was assessed at intervals of six months and one year after the start of treatment on the basis of the following criteria: (1) physiological measurements of the forced vital capacity (FVC) and the transfer coefficient (Kco), both expressed as percentages of the value predicted for the patient's age, sex, and height'4; (2) assessment of chest radiographic appearances (on the basis of the ILO U/C classification for the pneumoconioses'5) with an independent assessor.
HISTOLOGICAL ASSESSMENT
The histological assessment was performed on 11 lung samples by an independent observer without reference to other data on the patients. The samples were fixed in formalin, embedded in paraffin wax, sectioned, and stained with haematoxylin and eosin or elastic and van Gieson stains. A four point score, scale 1-4 (1 = normal, 2 = mild, 3 = moderate, 4 = severe), was used to assess the numbers of inflammatory cells in alveoli and interstitium and the severity of interstitial fibrosis and architectural destruction. This grading procedure was similiar to that used in previous studies.68 1619 SERUM COLLECTION Blood was taken from fasting patients, clotted for two hours at 37°C, and then centrifuged. The serum was separated and aliquots were stored at -20°C until they were used.
PROCOLLAGEN PEPTIDE MEASUREMENTS
The procollagen peptide measurements were made with radioimmune assay "kits", which were kindly provided by Dr Bremer of Hoechst Pharmaceuticals. The method was that of Rohde and colleagues.'2 The serum samples (diluted to 1:4, 1:16, and 1:64 with phosphate buffered saline) were incubated at 4°C overnight with prepared antiserum (raised in rabbits) to bovine type III procollagen. Excess procollagen peptide labelled with iodine 125 was added and the incubation continued for a further seven hours. Finally, the immune complexes were precipitated, with an excess of goat antiserum to rabbit IgG, and separated by centrifugation, and the amount of radioactivity in the precipitate was measured with a Packard autogamma scintillation spectrophotometer (S266). A standard curve (dilutions of a known amount of unlabelled procollagen peptide being used) was prepared by a similar method. The amount of procollagen which gave 50% inhibition of binding of labelled antigen was noted and used to calculate the concentration of procollagen peptide in the samples. For the con-728 struction of the standard curve all the measurements were carried out in triplicate where errors were less than 5%. Two constant serum samples were included in each kit to assess variation between kits. The variation between different kits was less than 25% and the variation within the same kit was less than 5%.
BIOCHEMICAL MEASUREMENTS OF TYPES I AND III COLLAGENS IN LUNG BIOPSY AND NECROPSY SAMPLES
In 12 cases the percentage of type III collagen, in the total of type I and type III collagen, was measured biochemically in open lung biopsy (8) or postmortem samples (4). The method used was developed in our laboratory20 and modified for use on human lung samples.6 It required the extraction of collagen by sodium dodecyl sulphate and its division into smaller peptides by cyanogen bromide. These were then separated by polyacrylamide gel electrophoresis and stained with Coomassie Blue. Finally, quantification was performed by densitometric scanning. The results were compared with the procollagen peptide concentrations taken just before biopsy or necropsy. SERUM 
FACTORS
To exclude patients with incidental liver disease from this study the serum aspartate transaminase (AST) activity was measured in all patients at the same time as the procollagen peptide sample. Serum AST activity was chosen as it had previously been found to show significant correlation with serum procollagen peptide concentration. ' There was no significant difference between the mean serum procollagen peptide concentration in normal subjects (8-8 (SD 2-3) ng/ml) and that in patients with non-fibrosing lung disorders (9-6 (3.0) ng/ml). The mean procollagen peptide concentration in the 60 patients with cryptogenic fibrosing alveolitis, however (10.4 (4.2) ng/ml), was significantly greater than the mean of the control samples (p < 0.01). Only one of the 10 patients in the non-fibrosing lung disorder group had a raised procollagen peptide concentration (that is, greater than the mean of the normal group + 2 SD), compared with 16 of the 60 (27%) patients with cryptogenic fibrosing alveolitis. Individual values for serum procollagen peptide concentration in the 23 patients with cryptogenic fibrosing alveolitis untreated at the time of sampling are shown in figure 1. Of these, 10 (that is, 44%) had procollagen peptide concentrations (mean + 2 SD) above control values. The mean procollagen peptide concentration of this group (12.6 (2.9) ng/ml) was significantly higher than that of the age and sex matched control group 
RELATIONSHIP BETWEEN SERUM PROCOLLAGEN PEPTIDE CONCENTRATION AND DEGREE OF FIBROSIS
There was no correlation between the serum procollagen peptide concentrations measured before biopsy or death and the degree of fibrosis as assessed histologically or the degree of cellularity, whether intra-alveolar or interstitial. Figure 3 shows the relationship between serum procollagen peptide concentrations before treatment and the subsequent changes in lung function one year later. The data show that the seven patients who showed an improvement in the percentage predicted Kco of greater than 10% one year after the -100 a. In view of the way in which type III procollagen peptides are produced, the raised concentrations found in cryptogenic fibrosing alveolitis are presumably the result of increased type III collagen synthesis (for review see reference 11). In animal models of pulmonary fibrosis in vitro22 23 and in vivo24 there is evidence for increased total collagen synthesis rates, although as yet there is no evidence of this in man. Fulmer and colleagues failed to demonstrate increased collagen synthesis in minced lung tissue from patients with cryptogenic fibrosing alveolitis,2 but the method used has been questioned.25 In animal models of pulmonary fibrosis, despite the increase in overall collagen synthesis rates, there is no evidence that the amount of type III collagen is Kirk, Bateman, Haslam, Laurent, Turner-Warwick increased more than that of type I collagen.222627 There is, however, some in vitro evidence of increased type I collagen synthesis. 28 Interestingly, serum procollagen peptide concentration, which presumably reflects type III collagen synthesis, is correlated with the proportion of type III collagen found in lung tissue. This implies that the proportion of type III collagen present in the lung tissue is related to changes in synthesis rates, although the possibility of changes in the rates of degradation cannot be excluded. The latter are believed to be important in pulmonary fibrosis in animal models.24 Furthermore, as the ratio of type III to type I collagen in lung tissue was measured in the present study, rather than the absolute amounts of type III collagen, the correlation with type III procollagen peptide concentrations implies that changes in the proportion of type III collagen in the lung do not depend entirely on changes in the amounts of type I collagen. Finally, the correlation with the proportion of type III collagen in the lung samples suggests that increases in the rate of type III collagen synthesis persist until changes in the amounts of type III in the lung occur. As previous evidence suggests that a greater proportion of type I than of type III collagen occurs in late disease,6 our results imply that increases in the rate of type III collagen synthesis occur before increases in the rate of type I collagen synthesis. Type I procollagen peptide concentrations were not measured in the present study, but as type I procollagen peptides are known to be cleaved more rapidly than type III peptides, they could possibly be a more sensitive indicator of overall collagen synthesis than type III procollagen peptide concentrations.
RELATIONSHIP BETWEEN SERUM PROCOLLAGEN PEPTIDE CONCENTRATION AND RESPONSE TO TREATMENT
Serum procollagen peptide measurements are easily and quickly made with the radioimmunoassay kit (now commercially available), and serial measurements may be carried out during the course of the disease with minimal discomfort to the patient. The technique therefore has the considerable advantage of simplicity and non-invasiveness over other methods of assessing disease activity, such as bronchopulmonary lavage"7 and lung biopsy. 8 6 Several factors may confuse the interpretation of procollagen peptide concentrations in patients with cryptogenic fibrosing alveolitis. The first problem is the lack of specificity for lung type III collagen previously mentioned, so that measurements of serum procollagen peptide concentration are appropriate only in patients with cryptogenic fibrosing alveolitis alone. In our study 17 of 71 patients were excluded because they had other associated conditions. Furthermore, the procollagen peptide concentrations found in cryptogenic fibrosing alveolitis are not as high as those found in some other conditions. In this study only type III procollagen peptide concentrations were measured; since it is probable, however, that in late cryptogenic fibrosing alveolitis the ratio of type I to type III collagen is 6 30 increased,3 measurement of type I procollagen peptide might prove useful as an additional method of "staging' the disease. In a study of patients with Paget' s disease by Taubman and colleagues3' the C-terminal peptide of type I procollagen peptide has been measured in serum in patients before and after treatment with disodium etidronate. The results were similar to those of the present study, showing abnormally high concentrations of type I procollagen peptide in the patients' serum which were reduced after treatment.
In our study of 11 cases there was no relationship between the degree of fibrosis assessed histologically and serum procollagen peptide concentration. This was possibly because the bulk of the collagen is type 136 and therefore a combination of type III and type I procollagen peptide concentrations would give a better estimation. A further reason may be that, as has been shown in animal models,7 changes in collagen metabolism occur before fibrosis becomes visible histologically. The study by Rohde and colleagues in liver disease did succeed in demonstrating a relationship between procollagen peptide concentrations and portal inflammation, periportal necrosis, and intralobular necrosis, but no relationship was found between portal and intralobular fibrosis and procollagen peptide levels. '2 Changes in procollagen peptide concentrations after commencement of treatment may be useful in the assessment of the response to treatment in patients with cryptogenic fibrosing alveolitis. Furthermore, serial procollagen peptide measurements may also prove to be useful in assessing patients during treatment, but detailed prospective studies need to be performed before their value in this respect can be assessed.
